MiR-93/106b and their host gene, MCM7, are differentially expressed in leiomyomas and functionally target F3 and IL-8

Molecular Endocrinology

Volumn 26, Issue 6, 2012, Pages 1028-1042

  Chuang, Tsai Der ^a   Luo, Xiaoping ^a   Panda, Harekrushna ^a   Chegini, Nasser ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7A; CASPASE 3; CASPASE 7; CONNECTIVE TISSUE GROWTH FACTOR; DOXYCYCLINE; F3 PROTEIN; GONADORELIN AGONIST; INTERLEUKIN 8; MEDROXYPROGESTERONE ACETATE; MICRORNA; MICRORNA 106B; MICRORNA 93; MINICHROMOSOME MAINTENANCE PROTEIN 7; ORAL CONTRACEPTIVE AGENT; PAI 1 PROTEIN; PROTEIN; SMALL INTERFERING RNA; THROMBOPLASTIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; AFRICAN AMERICAN; ARTICLE; CANCER CELL CULTURE; CAUCASIAN; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EXPOSURE; ENZYME ACTIVITY; FEMALE; GENE REPRESSION; GENE SILENCING; GENETIC TRANSDUCTION; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; LEIOMYOMA; LENTIVIRINAE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MYOMETRIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; TISSUE LEVEL;

ADULT; CASPASES; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CLUSTER ANALYSIS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-8; LEIOMYOMA; MENSTRUAL CYCLE; MICRORNAS; MIDDLE AGED; MYOMETRIUM; NUCLEAR PROTEINS; RNA INTERFERENCE; THROMBOPLASTIN; UTERINE NEOPLASMS; YOUNG ADULT;

EID: 84861210601     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2012-1075     Document Type: Article

References (64)

1. Kim YK, Heo I, Kim VN 2010 Modifications of small RNAs and their associated proteins. Cell 143:703-709
2. Medina PP, Slack FJ 2008 microRNAs and cancer: an overview. Cell Cycle 7:2485-2492
3. Ruvkun G 2008 The perfect storm of tiny RNAs. Nat Med 14: 1041-1045
4. Almeida MI, Reis RM, Calin GA 2011 MicroRNA history: discovery, recent applications, and next frontiers. Mutat Res 717:1-8
5. Cortez MA, Ivan C, Zhou P, Wu X, Ivan M, Calin GA 2010 microRNAs in cancer: from bench to bedside. Adv Cancer Res 108: 113-157
6. Lee YS, Dutta A 2009 MicroRNAs in cancer. Annu Rev Pathol 4:199-227
7. Schickel R, Boyerinas B, Park SM, Peter ME 2008 MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 27:5959-5974
8. Calin GA, Croce CM 2006 MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene 25:6202-6210
9. Pedeutour F, Quade BJ, Sornberger K, Tallini G, Ligon AH, Weremowicz S, Morton CC 2000 Dysregulation of HMGIC in a uterine lipoleiomyoma with a complex rearrangement including chromosomes 7, 12, and 14. Genes Chromosomes Cancer 27: 209-215
10. Vanharanta S, Wortham NC, Laiho P, Sjoberg J, Aittomaki K, Arola J, Tomlinson IP, Karhu A, Arango D, Aaltonen LA 2005 7q deletion mapping and expression profiling in uterine fibroids. Oncogene 24:6545-6554
11. Ishwad CS, Ferrell RE, Hanley K, Davare J, Meloni AM, Sandberg AA, Surti U 1997 Two discrete regions of deletion at 7q in uterine leiomyomas. Genes Chromosomes Cancer 19:156-160
12. Ligon AH, Morton CC 2001 Leiomyomata: heritability and cyto-genetic studies. Hum Reprod Update 7:8-14
13. Al-Hendy A, Salama SA 2006 Catechol-O-methyltransferase polymorphism is associated with increased uterine leiomyoma risk in different ethnic groups. J Soc Gynecol Investig 13:136-144
14. Denschlag D, Bentz EK, Hefler L, Pietrowski D, Zeillinger R, Tempfer C, Tong D 2006 Genotype distribution of estrogen receptor-, catechol-O-methyltransferase, and cytochrome P450 17 gene polymorphisms in Caucasian women with uterine leiomyomas. Fertil Steril 85:462-467
15. Pan Q, Luo X, Chegini N 2007 Genomic and proteomic profiling I: leiomyomas in African Americans and Caucasians. Reprod Biol Endocrinol 5:34
16. Hodge JC, Park PJ, Dreyfuss JM, Assil-Kishawi I, Somasundaram P, Semere LG, Quade BJ, Lynch AM, Stewart EA, Morton CC 2009 Identifying the molecular signature of the interstitial deletion 7q subgroup of uterine leiomyomata using a paired analysis. Genes Chromosomes Cancer 48:865-885
17. Forsburg SL 2008 The MCM helicase: linking checkpoints to the replication fork. Biochem Soc Trans 36:114-119
18. Fujioka S, Shomori K, Nishihara K, Yamaga K, Nosaka K, Araki K, Haruki T, Taniguchi Y, Nakamura H, Ito H 2009 Expression of minichromosome maintenance 7 (MCM7) in small lung adenocarcinomas (pT1): prognostic implication. Lung Cancer 65: 223-229
19. Li SS, Xue WC, Khoo US, Ngan HY, Chan KY, Tam IY, Chiu PM, Ip PP, Tam KF, Cheung AN 2005 Replicative MCM7 protein as a proliferation marker in endometrial carcinoma: a tissue microarray and clinicopathological analysis. Histopathology 46: 307-313
20. Ota T, Clayton AC, Minot DM, Shridhar V, Hartmann LC, Gilks CB, Chien JR 2011 Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in highgrade serous carcinomas of the ovary 1. Mod Pathol 24:277-287
21. Ren B, Yu G, Tseng GC, Cieply K, Gavel T, Nelson J, Michalopoulos G, Yu YP, Luo JH 2006 MCM7 amplification and over expression are associated with prostate cancer progression. Oncogene 25:1090-1098
22. Flynt AS, Lai EC 2008 Biological principles of microRNA-mediated regulation: shared themes amid diversity. Nat Rev Genet 9:831-842
23. Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, Iliopoulos D, Pilozzi E, Liu CG, Negrini M, Cavazzini L, Volinia S, Alder H, Ruco LP, Baldassarre G, Croce CM, Vecchione A 2008 E2F1-regulated microRNAs impair TGF-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 13:272-286
24. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, Newman J, Bronson RT, Crowley D, Stone JR, Jaenisch R, Sharp PA, Jacks T 2008 Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 132:875-886
25. Kan T, Sato F, Ito T, Matsumura N, David S, Cheng Y, Agarwal R, Paun BC, Jin Z, Olaru AV, Selaru FM, Hamilton JP, Yang J, Abraham JM, Mori Y, Meltzer SJ 2009 The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. Gastroenterology 136:1689-1700
26. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G, Rameh L, Loda M, Pandolfi PP 2010 Identification of the miR-106b 25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation 3. Sci Signal 3:ra29
27. Marsh EE, Lin Z, Yin P, Milad M, Chakravarti D, Bulun SE 2008 Differential expression of microRNA species in human uterine leiomyoma versus normal myometrium. Fertil Steril 89:1771-1776
28. Pan Q, Luo X, Chegini N 2008 Differential expression of microRNAs in myometrium and leiomyomas and regulation by ovarian steroids. J Cell Mol Med 12:227-240
29. Wang H, Mahadevappa M, Yamamoto K, Wen Y, Chen B, Warrington JA, Polan ML 2003 Distinctive proliferative phase differences in gene expression in human myometrium and leiomyomata. Fertil Steril 80:266-276
30. Zavadil J, Ye H, Liu Z, Wu J, Lee P, Hernando E, Soteropoulos P, Toruner GA, Wei JJ 2010 Profiling and functional analyses of microRNAs and their target gene products in human uterine leiomyomas. PLoS ONE 5:e12362
31. Dahia N, Sherman-Baust CA, Wang TL, Davidson B, Shih IeM, Zhang Y, Wood 3rd W, Becker KG, Morin PJ 2008 MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS ONE 3:e2436
32. Inomata M, Tagawa H, Guo YM, Kameoka Y, Takahashi N, Sawada K 2009 MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood 113: 396-402
33. Albrektsen T, Sorensen BB, Hjortø GM, Fleckner J, Rao LV, Petersen LC 2007 Transcriptional program induced by factor VIIa-tissue factor, PAR1 and PAR2 in MDA-MB-231 cells. J Thromb Haemost 5:1588-1597
34. Krikun G, Lockwood CJ, Paidas MJ 2009 Tissue factor and the endometrium: from physiology to pathology. Thromb Res 124: 393-396
35. Wang T, Zhang X, Obijuru L, Laser J, Aris V, Lee P, Mittal K, Soteropoulos P, Wei JJ 2007 A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer 46:336-347
36. Bhat-Nakshatri P, Wang G, Collins NR, Thomson MJ, Geistlinger TR, Carroll JS, Brown M, Hammond S, Srour EF, Liu Y, Nakshatri H 2009 Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res 37: 4850-4861
37. Luo X, Chegini N 2008 The expression and potential regulatory function of microRNAs in the pathogenesis of leiomyoma. Semin Reprod Med 26:500-514
38. Yamagata K, Fujiyama S, Ito S, Ueda T, Murata T, Naitou M, Takeyama K, Minami Y, O'Malley BW, Kato S 2009 Maturation of microRNA is hormonally regulated by a nuclear receptor. Mol Cell 36:340-347
39. Lau KM, Chan QK, Pang JC, Li KK, Yeung WW, Chung NY, Lui PC, Tam YS, Li HM, Zhou L, Wang Y, Mao Y, Ng HK 2010 Minichromosome maintenance proteins 2, 3 and 7 in medulloblastoma: overexpression and involvement in regulation of cell migration and invasion. Oncogene 29:5475-5489
40. Nishihara K, Shomori K, Fujioka S, Tokuyasu N, Inaba A, Osaki M, Ogawa T, Ito H 2008 Minichromosome maintenance protein 7 in colorectal cancer: implication of prognostic significance. Int J Oncol 33:245-251
41. Du L, Schageman JJ, Subauste MC, Saber B, Hammond SM, Prud-kin L, Wistuba II, Ji L, Roth JA, Minna JD, Pertsemlidis A 2009 miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res 7:1234-1243
42. Fang L, Deng Z, Shatseva T, Yang J, Peng C, Du WW, Yee AJ, Ang LC, He C, Shan SW, Yang BB 2011 MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-α8 3. Oncogene 30:806-821
43. Long J, Wang Y, Wang W, Chang BH, Danesh FR 2010 Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. J Biol Chem 285: 23457-23465
44. Wang H, Liu J, Zong Y, Xu Y, Deng W, Zhu H, Liu Y, Ma C, Huang L, Zhang L, Qin C 2010 miR-106b aberrantly expressed in a double transgenic mouse model for Alzheimer's disease targets TGF-α type II receptor. Brain Res 1357:166-174
45. Li Y, Tan W, Neo TW, Aung MO, Wasser S, Lim SG, Tan TM 2009 Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci 100:1234-1242
46. Senturk LM, Sozen I, Gutierrez L, Arici A 2001 Interleukin 8 production and interleukin 8 receptor expression in human myometrium and leiomyoma. Am J Obstet Gynecol 184:559-566
47. Liu X, Nie J, Guo SW 2011 Elevated immunoreactivity to tissue factor and its association with dysmenorrhea severity and the amount of menses in adenomyosis. Hum Reprod 26:337-345
48. Lockwood CJ, Murk W, Kayisli UA, Buchwalder LF, Huang ST, Funai EF, Krikun G, Schatz F 2009 Progestin and thrombin regulate tissue factor expression in human term decidual cells. J Clin Endocrinol Metab 94:2164-2170
49. Runic R, Schatz F, Krey L, Demopoulos R, Thung S, Wan L, Lockwood CJ 1997 Alterations in endometrial stromal cell tissue factor protein and messenger ribonucleic acid expression in patients experiencing abnormal uterine bleeding while using Norplant-2 contraception. J Clin Endocrinol Metab 82:1983-1988
50. Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, Felding-Habermann B, Takada Y, Mueller BM, Ruf W 2008 Inhibition of tissue factor signaling suppresses tumor growth. Blood 111:190-199
51. Chegini N 2010 Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder. Semin Reprod Med 28:180-203
52. Pendurthi UR, Allen KE, Ezban M, Rao LV 2000 Factor VIIa and thrombin induce the expression of Cyr61 and connective tissue growth factor, extracellular matrix signaling proteins that could act as possible downstream mediators in factor VIIa x tissue factorinduced signal transduction. J Biol Chem 275:14632-14641
53. Pendurthi UR, Tran TT, Post M, Rao LV 2005 Proteolysis of CCN1 by plasmin: functional implications. Cancer Res 65:9705-9711
54. Cheng Z, Xie Y, Dai H, Hu L, Zhu Y, Gong J 2008 Unequal tissue expression of proteins from the PA/PAI system, myoma necrosis, and uterus survival after uterine artery occlusion. Int J Gynaecol Obstet 102:55-59
55. Sourla A, Polychronakos C, Zeng WR, Nepveu A, Kukuvitis A, Naud F, Koutsilieris M 1996 Plasminogen activator inhibitor 1 messenger RNA expression and molecular evidence for del(7)(q22) in uterine leiomyomas. Cancer Res 56:3123-3128
56. Leask A 2010 Potential therapeutic targets for cardiac fibrosis. Circ Res 106:1675-1680
57. Inforzato A, Baldock C, Jowitt TA, Holmes DF, Lindstedt R, Marcellini M, Rivieccio V, Briggs DC, Kadler KE, Verdoliva A, Bottazzi B, Mantovani A, Salvatori G, Day AJ 2010 The angiogenic inhibitor long pentraxin PTX3 forms an asymmetric octamer with two binding sites for FGF2. J Biol Chem 285:17681-17692
58. Napoleone E, Di Santo A, Bastone A, Peri G, Mantovani A, de Gaetano G, Donati MB, Lorenzet R 2002 Long pentraxin PTX3 upregulates tissue factor expression in human endothelial cells: a novel link between vascular inflammation and clotting activation. Arterioscler Thromb Vasc Biol 22:782-787
59. Norata GD, Marchesi P, Pulakazhi Venu VK, Pasqualini F, Anselmo A, Moalli F, Pizzitola I, Garlanda C, Mantovani A, Catapano AL 2009 Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 120:699-708
60. Varani S, Elvin JA, Yan C, DeMayo J, DeMayo FJ, Horton HF, Byrne MC, Matzuk MM 2002 Knockout of pentraxin 3, a down-stream target of growth differentiation factor-9, causes female sub-fertility. Mol Endocrinol 16:1154-1167
61. Chegini N, Ma C, Tang XM, Williams RS 2002 Effects of GnRH analogues,'add-back' steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-expression. Mol Hum Reprod 8:1071-1078
62. Chuang TD, Guh JY, Chiou SJ, Chen HC, Huang JS, Yang YL, Chuang LY 2007 Phosphoinositide 3-kinase is required for high glucose-induced hypertrophy and p21WAF1 expression in LLC-PK1 cells. Kidney Int 71:867-874
63. Ding L, Xu J, Luo X, Chegini N 2004 Gonadotropin releasing hormone and transforming growth factor activate mitogen-activated protein kinase/extracellularly regulated kinase and differentially regulate fibronectin, type I collagen, and plasminogen activator inhibitor-1 expression in leiomyoma and myometrial smooth muscle cells. J Clin Endocrinol Metab 89:5549-5557
64. Yu Z, Willmarth NE, Zhou J, Katiyar S, Wang M, Liu Y, McCue PA, Quong AA, Lisanti MP, Pestell RG 2010 microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci USA 107:8231-8236